The global EPO Biomarkers market is anticipated to grow at a modest CAGR of around 5.3% during the forecast period (2021-2027). EPO is produced by the kidneys and is a factor responsible for regulating red blood cell (RBC) production in mammals. Some of the EPO biomarkers available in the market are epoetin alfa, epoetin beta, epoetin zeta, epoetin theta, recombinant human erythropoietin, and darbepoetin alfa. Among these, the erythropoietin alfa is used to treat anemia and cancer cells and it increases the count of red blood cells in the body. Moreover, the erythropoietin biomarkers are used to treat end-stage renal diseases (ESRD), and anemia induced from multiple myeloma, cancer, and AIDS-associated anemia.
To Request a Sample of our Report on EPO Biomarkers Market: https://www.omrglobal.com/request-sample/epo-biomarkers-market
The rising prevalence of chronic kidney disease (CKD) is the major factor driving the EPO Biomarkers demands in various end-users. According to the CDC estimates for 2021, the number of American adults who have chronic kidney disease (CKD) is now estimated to be 37 million, which is 15% of the total population. Several factors including an aging population and increased prevalence of risk factors such as diabetes and hypertension are the major cause of CKDs according to CDC. The reason behind the prevalence of chronic kidney diseases is that the people who have CKDs are not aware of it. One of every two people with very low kidney function, and who are not on dialysis, don’t know they have CKD. The National Kidney Foundation (NKF) estimates that one of every three adults – some 80 million people – is at risk for CKD.
Moreover, the approvals of the drugs produced by major players also enhancing the market growth. For instance, in June 2020, Kyowa Kirin Co., Ltd., announced that Duvroq, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), from GSK, had been approved in Japan by the Ministry of Health, Labour and Welfare. The drug found its use for the treatment of patients with renal anemia due to CKD. Besides, in Sept 2019, the INVOKANA (Canagliflozin) drug produced by the Janssen Pharmaceutical Companies of Johnson & Johnson got the approval from US FDA. The drug is used to reduce the risk of end-stage kidney disease (ESKD) and cardiovascular events in patients with Type 2 diabetes and CKD. Thus, the approvals will help manufacturers to increase their production to fulfil the market demands, which will further expected to boost the market growth.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
Segment Covered-
- By Biomarker Type
- By Applications
- By End-User
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape- Amgen Inc, BioAgilytix Labs, Novartis AG, Pfizer Inc., Thermo Fisher Scientific Inc, F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., Agilent Technologies, Inc, among others.
(Get 15% Discount on Buying this Report)
A full Report of EPO Biomarkers Market is Available at: https://www.omrglobal.com/industry-reports/epo-biomarkers-market
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How COVID-19 impacted the market?
Ø Deviation from the pre-COVID-19 forecast
Ø Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global EPO Biomarkers Market Report Segment
By Biomarker Type
- Erythropoietin Alfa
- Erythropoietin Beta
- Erythropoietin Zeta
- Erythropoietin Theta
- Recombinant Human Erythropoietin
- Darbepoietin Alfa
By Applications
- End-Stage Renal Disorder
- Cancers
- Rheumatoid Arthritis
- AIDS
- Neurology
- Hematology
- Others (Anaemia of Chronic Inflammatory Syndromes)
By End Users
- Diagnostic Centres
- Ambulatory Care and Surgical Centres
- Hospitals
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
